Five things to know:
1. The patent is titled “pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury.”
2. It covers processes that involve injecting OPCs obtained from a pluripotent human stem cell line into the spinal cord injury site and covers human embryonic and induced pluripotent stem cell-derived OPCs.
3. OPC1 cells are created by directing the developmental lineage of pluripotent cell lines to produce a consistent population of oligodendritic cells, which aim to provide post-injury regeneration for patients.
4. OPC1 is being tested in a Phase I/IIa clinical trial for the treatment of acute spinal cord injuries.
5. The patent expires in 2036.
More articles on biologics:
Dr. Manny Sethi to step down from nonprofit to focus on US Senate campaign
Why 2019 is shaping up to be an important year for Zimmer Biomet — 5 things to know
Husband-wife neurosurgeon team bring 24-hour neurosurgery back to Arkansas hospital
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
